Al Reising

Q: What is Al Reising email address?

Email Al Reising at al.reising@novartis.com. This email is the most updated Al Reising email found in 2026.

Q: How to contact Al Reising?

To contact Al Reising send an email to al.reising@novartis.com. (updated on October 30, 2024)

Global Biomarker Diagnostic Director at Novartis Oncology | Summit, New Jersey, United States

About Al Reising

Al Reising currently serves as the Global Biomarker Diagnostic Director at Novartis Oncology, where he leverages his extensive expertise in companion diagnostics and translational biomarker development to drive innovative solutions in cancer treatment. With a robust background in pharmaceutical science, Al excels in managing complex international projects that require meticulous coordination among cross-functional teams. His leadership is characterized by a strong emphasis on collaboration, ensuring that scientists and stakeholders from diverse backgrounds work seamlessly together to advance clinical biomarker strategies.

In his role, Al is instrumental in overseeing the development of companion diagnostics that are critical for personalized medicine. He is adept at navigating the intricacies of clinical testing across multiple projects, engaging with various diagnostic partners to ensure that the biomarkers identified are both clinically relevant and actionable. His comprehensive knowledge of drug discovery and preclinical development, coupled with his hands-on experience in GLP and GMP regulated environments, positions him as a key player in the advancement of oncology therapeutics.

Al's commitment to excellence is further reflected in his ability to manage dynamic teams within a fast-paced toxicology lab setting. He fosters an environment of innovation and accountability, empowering scientists to explore new avenues in in vitro and in vivo research. His proficiency in project management and clinical research enables him to effectively align strategic objectives with operational execution, ultimately contributing to the successful delivery of groundbreaking therapies that improve patient outcomes. As a thought leader in the pharmaceutical industry, Al Reising continues to push the boundaries of what is possible in biomarker diagnostics, making significant contributions to the future of cancer care.

Al Reising Work